Baker Bros. Advisors L.P. 13F annual report
Baker Bros. Advisors L.P. is an investment fund managing more than $17.2 trillion ran by Alexandra Toohey. There are currently 99 companies in Mrs. Toohey’s portfolio. The largest investments include Seagen Inc and BeiGene Ltd, together worth $11.6 trillion.
$17.2 trillion Assets Under Management (AUM)
As of 7th November 2023, Baker Bros. Advisors L.P.’s top holding is 44,554,162 shares of Seagen Inc currently worth over $9.45 trillion and making up 54.9% of the portfolio value.
Relative to the number of outstanding shares of Seagen Inc, Baker Bros. Advisors L.P. owns more than 0.2% of the company.
In addition, the fund holds 11,668,897 shares of BeiGene Ltd worth $2.1 trillion, whose value fell approximately 0.1% in the past six months.
The third-largest holding is Incyte worth $2.09 trillion and the next is Acadia Pharmaceuticals Inc worth $893 billion, with 42,864,612 shares owned.
Currently, Baker Bros. Advisors L.P.'s portfolio is worth at least $17.2 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Baker Bros. Advisors L.P.
The Baker Bros. Advisors L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Alexandra Toohey serves as the Chief Financial Officer at Baker Bros. Advisors L.P..
Recent trades
In the most recent 13F filing, Baker Bros. Advisors L.P. revealed that it had opened a new position in
Immunovant Inc and bought 425,009 shares worth $16.3 billion.
This means they effectively own approximately 0.1% of the company.
Immunovant Inc makes up
approximately 0.1%
of the fund's Health Care sector allocation and has grown its share price by 159.9% in the past year.
The investment fund also strengthened its position in Incyte by buying
510 additional shares.
This makes their stake in Incyte total 36,178,566 shares worth $2.09 trillion.
Incyte dropped 31.1% in the past year.
On the other hand, there are companies that Baker Bros. Advisors L.P. is getting rid of from its portfolio.
Baker Bros. Advisors L.P. closed its position in Chinook Therapeutics on 14th November 2023.
It sold the previously owned 1,455,202 shares for $55.9 billion.
Alexandra Toohey also disclosed a decreased stake in Argenx Se by 0.5%.
This leaves the value of the investment at $74.3 billion and 151,215 shares.
One of the largest hedge funds
The two most similar investment funds to Baker Bros. Advisors L.P. are Epoch Investment Partners and Harding Loevner L.P.. They manage $17.2 trillion and $17.1 trillion respectively.
Alexandra Toohey investment strategy
Baker Bros. Advisors L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 95.9% of
the total portfolio value.
The fund focuses on investments in the United States as
60.6% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
8% of the total holdings value.
On the other hand, large-cap stocks make up only 4.0% of the portfolio.
The average market cap of the portfolio companies is close to $2.25 billion.
The complete list of Baker Bros. Advisors L.P. trades based on 13F SEC filings
These positions were updated on November 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Seagen Inc |
No change
44,554,162
|
$9,452,165,468,000 | 54.91% |
| BeiGene Ltd |
No change
11,668,897
|
$2,098,884,503,000 | 12.19% |
| Incyte Corp. |
0.00%
36,178,566
|
$2,090,035,758,000 | 12.14% |
| Acadia Pharmaceuticals Inc |
No change
42,864,612
|
$893,298,514,000 | 5.19% |
| Biomarin Pharmaceutical Inc. |
No change
3,810,248
|
$337,130,743,000 | 1.96% |
| Madrigal Pharmaceuticals Inc |
No change
1,545,113
|
$225,648,303,000 | 1.31% |
| Rhythm Pharmaceuticals Inc. |
3.14%
6,702,349
|
$153,651,351,000 | 0.89% |
| Roivant Sciences Ltd. |
25.97%
11,877,171
|
$138,725,357,000 | 0.81% |
| Immunocore Holdings Plc |
No change
2,520,731
|
$130,825,939,000 | 0.76% |
| Akero Therapeutics Inc |
No change
2,368,378
|
$119,792,559,000 | 0.70% |
| AbCellera Biologics Inc. |
26.22%
20,763,323
|
$95,511,286,000 | 0.55% |
| Biocryst Pharmaceuticals Inc. |
No change
12,710,818
|
$89,992,591,000 | 0.52% |
| Replimune Group Inc |
No change
4,578,280
|
$78,334,371,000 | 0.46% |
| Entrada Therapeutics, Inc. |
No change
4,865,819
|
$76,879,940,000 | 0.45% |
| Revolution Medicines Inc |
No change
2,691,493
|
$74,500,526,000 | 0.43% |
| Argenx Se |
46.03%
151,215
|
$74,341,830,000 | 0.43% |
| SpringWorks Therapeutics, Inc. |
No change
2,999,846
|
$69,356,440,000 | 0.40% |
| Kymera Therapeutics, Inc. |
8.57%
4,750,400
|
$66,030,560,000 | 0.38% |
| Immatics N.v. |
No change
5,640,816
|
$65,320,649,000 | 0.38% |
| Mirati Therapeutics Inc |
No change
1,409,784
|
$61,410,191,000 | 0.36% |
| Chinook Therapeutics, Inc. |
Closed
1,455,202
|
$55,908,861,000 | |
| Kiniksa Pharmaceuticals Ltd |
No change
2,809,577
|
$48,802,352,000 | 0.28% |
| Ultragenyx Pharmaceutical Inc. |
74.51%
1,366,547
|
$48,717,401,000 | 0.28% |
| Dice Therapeutics, Inc. |
Closed
1,035,786
|
$48,122,618,000 | |
| Denali Therapeutics Inc |
57.49%
2,292,003
|
$47,284,022,000 | 0.27% |
| Prelude Therapeutics Inc |
No change
10,123,824
|
$31,282,616,000 | 0.18% |
| Kodiak Sciences Inc |
No change
17,310,490
|
$31,158,882,000 | 0.18% |
| Nurix Therapeutics, Inc. |
No change
3,882,125
|
$30,513,503,000 | 0.18% |
| Biomea Fusion, Inc. |
No change
2,108,949
|
$29,019,138,000 | 0.17% |
| Immunogen, Inc. |
Closed
1,520,097
|
$28,684,230,000 | |
| IDEAYA Biosciences, Inc. |
No change
1,062,123
|
$28,656,079,000 | 0.17% |
| Cerus Corp. |
7.29%
17,239,501
|
$27,927,992,000 | 0.16% |
| Aerovate Therapeutics, Inc. |
No change
1,963,479
|
$26,644,410,000 | 0.15% |
| IGM Biosciences, Inc. |
0.02%
3,157,764
|
$26,367,329,000 | 0.15% |
| Xenon Pharmaceuticals Inc |
No change
751,639
|
$25,675,988,000 | 0.15% |
| Cabaletta Bio Inc |
No change
1,594,000
|
$24,260,680,000 | 0.14% |
| Monte Rosa Therapeutics, Inc. |
62.57%
4,916,095
|
$23,548,095,000 | 0.14% |
| Dbv Technologies S.a. |
No change
14,614,264
|
$19,875,399,000 | 0.12% |
| Krystal Biotech Inc |
No change
169,934
|
$19,712,344,000 | 0.11% |
| Verve Therapeutics, Inc. |
No change
1,416,530
|
$18,783,188,000 | 0.11% |
| Bicycle Therapeutics plc |
No change
843,814
|
$16,952,223,000 | 0.10% |
| Immunovant Inc |
Opened
425,009
|
$16,316,096,000 | 0.09% |
| Cogent Biosciences, Inc. |
31.99%
1,292,966
|
$12,606,419,000 | 0.07% |
| Day One Biopharmaceuticals, Inc. |
No change
1,000,000
|
$12,270,000,000 | 0.07% |
| Verastem Inc |
Closed
1,336,485
|
$9,943,448,000 | |
| Prime Medicine, Inc. |
No change
1,028,466
|
$9,811,566,000 | 0.06% |
| 2seventy Bio, Inc. |
No change
2,497,526
|
$9,790,302,000 | 0.06% |
| Relay Therapeutics, Inc. |
No change
1,160,117
|
$9,756,584,000 | 0.06% |
| Pacific Biosciences of California Inc |
No change
1,127,782
|
$9,416,980,000 | 0.05% |
| Insmed Inc |
No change
343,000
|
$8,660,750,000 | 0.05% |
| Adaptimmune Therapeutics Plc |
No change
10,969,282
|
$8,556,040,000 | 0.05% |
| Tango Therapeutics, Inc. |
No change
750,000
|
$8,445,000,000 | 0.05% |
| Heron Therapeutics Inc |
No change
8,131,678
|
$8,375,628,000 | 0.05% |
| Arvinas Inc |
Opened
413,481
|
$8,120,767,000 | 0.05% |
| Fate Therapeutics Inc |
Closed
1,671,717
|
$7,957,373,000 | |
| Taysha Gene Therapies, Inc. |
Opened
2,504,756
|
$7,915,029,000 | 0.05% |
| Allogene Therapeutics Inc |
Closed
1,576,901
|
$7,837,198,000 | |
| Sana Biotechnology, Inc. |
No change
2,000,000
|
$7,740,000,000 | 0.04% |
| Bluebird bio Inc |
No change
2,499,715
|
$7,599,134,000 | 0.04% |
| Ars Pharmaceuticals, Inc. |
No change
2,006,451
|
$7,584,385,000 | 0.04% |
| Sagimet Biosciences Inc. |
Opened
815,359
|
$7,175,159,000 | 0.04% |
| Tscan Therapeutics, Inc. |
No change
2,784,792
|
$7,129,068,000 | 0.04% |
| Geron Corp. |
No change
3,061,224
|
$6,489,795,000 | 0.04% |
| Athira Pharma, Inc. |
No change
3,153,807
|
$6,370,690,000 | 0.04% |
| Alector, Inc. |
No change
964,851
|
$6,252,234,000 | 0.04% |
| Mirum Pharmaceuticals Inc |
Opened
190,476
|
$6,019,042,000 | 0.03% |
| Edgewise Therapeutics, Inc. |
109.94%
1,049,699
|
$6,014,775,000 | 0.03% |
| Summit Therapeutics Inc |
50.19%
3,140,473
|
$5,872,685,000 | 0.03% |
| Stoke Therapeutics, Inc. |
30.25%
1,485,915
|
$5,854,505,000 | 0.03% |
| Hookipa Pharma Inc |
82.25%
8,065,398
|
$4,968,285,000 | 0.03% |
| Morphic Holding Inc |
Opened
215,800
|
$4,943,978,000 | 0.03% |
| Celcuity Inc |
Opened
535,478
|
$4,894,269,000 | 0.03% |
| Neoleukin Therapeutics, Inc. |
Opened
1,221,414
|
$4,824,585,000 | 0.03% |
| Aadi Bioscience, Inc. |
No change
989,928
|
$4,791,252,000 | 0.03% |
| Macrogenics Inc |
Closed
892,579
|
$4,775,298,000 | |
| Mereo BioPharma Group plc |
Closed
3,554,979
|
$4,692,572,000 | |
| Opthea Limited |
0.02%
2,690,891
|
$4,687,532,000 | 0.03% |
| Natera Inc |
No change
100,000
|
$4,425,000,000 | 0.03% |
| Aravive Inc |
Closed
3,261,224
|
$4,109,142,000 | |
| Design Therapeutics, Inc. |
200.00%
1,500,000
|
$3,540,000,000 | 0.02% |
| Praxis Precision Medicines, Inc. |
No change
1,879,915
|
$3,214,655,000 | 0.02% |
| Neoleukin Therapeutics, Inc. |
Closed
3,821,740
|
$3,172,044,000 | |
| Compass Therapeutics, Inc. |
No change
1,557,630
|
$3,068,531,000 | 0.02% |
| Talis Biomedical Corporation |
93.33%
508,323
|
$2,933,024,000 | 0.02% |
| Gracell Biotechnologies Inc. |
No change
1,000,000
|
$2,880,000,000 | 0.02% |
| Sera Prognostics, Inc. |
14.75%
1,515,342
|
$2,818,536,000 | 0.02% |
| Vaxcyte, Inc. |
No change
48,885
|
$2,492,157,000 | 0.01% |
| Xencor Inc |
No change
123,127
|
$2,481,009,000 | 0.01% |
| Kala Bio Inc. |
129.42%
266,613
|
$2,372,856,000 | 0.01% |
| Vera Therapeutics, Inc. |
Closed
146,464
|
$2,350,747,000 | |
| Achilles Therapeutics Plc |
No change
2,557,149
|
$2,326,750,000 | 0.01% |
| Century Therapeutics, Inc. |
No change
1,149,340
|
$2,298,680,000 | 0.01% |
| Affimed N.V. |
32.56%
4,448,644
|
$2,126,007,000 | 0.01% |
| Perspective Therapeutics Inc |
229.40%
7,639,703
|
$2,090,987,000 | 0.01% |
| Instil Bio, Inc. |
10.80%
4,704,395
|
$2,013,481,000 | 0.01% |
| Pmv Pharmaceuticals Inc |
No change
322,024
|
$1,977,227,000 | 0.01% |
| AnaptysBio Inc |
86.31%
106,197
|
$1,907,298,000 | 0.01% |
| Point Biopharma Global Inc. |
78.62%
249,968
|
$1,667,287,000 | 0.01% |
| iTeos Therapeutics, Inc. |
No change
150,346
|
$1,646,289,000 | 0.01% |
| Leap Therapeutics Inc |
No change
1,172,175
|
$1,617,602,000 | 0.01% |
| Aligos Therapeutics, Inc. |
No change
2,076,400
|
$1,551,071,000 | 0.01% |
| Aeglea BioTherapeutics Inc |
Closed
3,410,106
|
$1,536,253,000 | |
| Mersana Therapeutics Inc |
No change
1,086,115
|
$1,379,366,000 | 0.01% |
| Vor Biopharma Inc. |
No change
633,848
|
$1,343,758,000 | 0.01% |
| Invitae Corp |
80.13%
1,764,546
|
$1,067,903,000 | 0.01% |
| Avidity Biosciences, Inc. |
79.19%
166,347
|
$1,061,294,000 | 0.01% |
| Atreca Inc |
No change
3,532,760
|
$922,050,000 | 0.01% |
| FibroGen Inc |
Closed
238,084
|
$642,827,000 | |
| Nkarta, Inc. |
Closed
271,329
|
$594,211,000 | |
| Genetron Holdings Limited |
No change
455,306
|
$369,754,000 | 0.00% |
| Protara Therapeutics Inc |
No change
199,671
|
$333,451,000 | 0.00% |
| Vincerx Pharma, Inc. |
Closed
225,579
|
$293,253,000 | |
| Foghorn Therapeutics Inc. |
No change
45,027
|
$225,135,000 | 0.00% |
| Surrozen, Inc. |
No change
833,333
|
$34,250,000 | 0.00% |
| No transactions found | |||
| Showing first 500 out of 114 holdings | |||
Hedge funds similar to Baker Bros. Advisors L.P.
- Glenmede Trust Co Na
- Rafferty Asset Management
- Fred Alger Management
- Jacobs Levy Equity Management, Inc
- Fuller & Thaler Asset Management, Inc
- Earnest Partners
- Epoch Investment Partners
- Harding Loevner L.P.
- Temasek (private) Ltd
- Dnb Asset Management As
- Ae Wealth Management
- Bridgewater Associates, L.P.
- Panagora Asset Management Inc
- Davis Selected Advisers